Not provided
Not provided
Not provided
Not provided
Low accrual
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The COVID-19 pandemic has had a dramatic effect in public health worldwide. In Brazil, there have been more than 2 million confirmed cases and over 75,000 deaths since February 26, 2020. Based on reports of a hyperinflammatory state associated with COVID-19, the use of immunosuppressive drugs may be efficacious in the treatment of this disease. JAK inhibitors have been shown to harness inflammation in a number of different pathologic conditions. The aim of the present study is to evaluate the efficacy and safety of JAK inhibitor ruxolitinib in patients with acute respiratory distress syndrome due to COVID-19.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental Group - ruxolitinib | Experimental | Ruxolitinib 5 mg PO b.i.d. for 14 days |
|
| Placebo Group | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Janus Kinase Inhibitor (ruxolitinib) | Drug | 5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils < 500/mm3 or platelets <50,000/mm3. |
|
| Measure | Description | Time Frame |
|---|---|---|
| A composite outcome of death or ICU admission or mechanical ventilation at day 14. | 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| A composite outcome of death or ICU admission or mechanical ventilation at day 28 | 28 days | |
| Time to treatment failure | ICU admission, mechanical ventilation, death or consent withdrawal | 28 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital das Clínicas | São Paulo | 05403-000 | Brazil |
Not provided
| ID | Term |
|---|---|
| D000075242 | Janus Kinase Inhibitors |
| C540383 | ruxolitinib |
| ID | Term |
|---|---|
| D047428 | Protein Kinase Inhibitors |
| D004791 | Enzyme Inhibitors |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Placebo tablets P.O. b.i.d. for 14 days. |
|
| Overall survival at days 14 and 28 | 14 and 28 days |
| Cumulative incidence of ICU admission rate at days 14 and 28 | 14 and 28 days |
| Cumulative incidence of mechanical ventilation at days 14 and 28 | 14 and 28 days |
| Duration of hospital stay | 28 days |
| Duration of ICU stay | 28 days |
| Duration of mechanical ventilation | 28 days |
| Duration of non-invasive ventilation | 28 days |
| Secondary hemophagocytic syndrome rate | 28 days |
| Cumulative incidence nosocomial infection rate at days 14 and 28 | 14 and 28 days |
| Incidence of discontinuation of oxygen supplementation at days 14 and 28 | 14 and 28 days |
| Rate of grade 1-2 and 3-5 emerging adverse events at day 28 | 28 days |
| Cumulative dose of methylprednisolone at days 14 and 28 | 14 and 28 days |
| Change in PaO2/FiO2 ratio from baseline to days 14 and 28 | 14 and 28 days |
| Change in interleukin 6 levels [pg/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in d-dimer levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in fibrinogen levels [mg/dL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in ferritin levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in C reactive protein levels [mg/L] from baseline to days 14 and 28 | 14 and 28 days |
| Change in alanine aminotransferase [U/L] from baseline to days 14 and 28 | 14 and 28 days |
| Change in aspartate aminotransferase [U/L] from baseline to days 14 and 28 | 14 and 28 days |
| Change in creatinine levels [mg/dL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in glucose levels [mg/dL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in hemoglobin levels [g/dL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in platelet count [x10ˆ3/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days |
| Change in absolute neutrophil count [x10ˆ3/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days |
| Change in absolute neutrophil count [/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days |
| Change in absolute lymphocyte count [/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days |
| Change in prothrombin time ratio from baseline to days 14 and 28 | 14 and 28 days |
| Change in partial thromboplastin time ratio from baseline to days 14 and 28 | 14 and 28 days |
| Change in bilirubin [mg/dl] from baseline to days 14 and 28 | 14 and 28 days |
| Change in lactate dehydrogenase [U/L] from baseline to days 14 and 28 | 14 and 28 days |
| Change in CPK-MB [ng/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in troponin [ng/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in von Willebrand factor antigen level (VWF:Ag) [%] from baseline to days 14 and 28 | 14 and 28 days |
| Change in von Willebrand factor activity (ristocetin cofactor) [%] from baseline to days 14 and 28 | 14 and 28 days |
| Change in ADAMTS-13 [%] from baseline to days 14 and 28 | 14 and 28 days |
| Change in von Willebrand multimeters from baseline to days 14 and 28 | 14 and 28 days |
| Change in plasminogen activator inhibitor-1 levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in E-selectin levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in P-selectin levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in endothelin [fmol/mL] from baseline to days 14 and 28 | 14 and 28 days |
| Change in circulating microparticles from baseline to days 14 and 28 | 14 and 28 days |
| Change in thromboelastography from baseline to days 14 and 28 | 14 and 28 days |
| D020164 | Chemical Actions and Uses |